Genotype |
Grade 3-4 toxicities |
Number
of patients |
Regimen of chemotherapy |
Homozygous GG 1627A>G* |
Grade 3 neutropenia
Grade 4 neutropenia |
2
2 |
FAC, CMF
5-FU+CDDP, FOLFIRI |
Heterozygous GA 967G>A ** |
Grade 3 neutropenia |
1 |
FOLFOX4 |
Heterozygous CT 1774C>T ** |
Grade 3 neutropenia |
1 |
5-FU+Leucovorin |
Heterozygous IVS14+G>A |
Grade 4 neutropenia |
1 |
5-FU+Leucovorin |
Heterozygous AT 1011A>T |
None |
1 |
FAC |
Heterozygous GA 1236G>A |
Grade 4 neutropenia |
1 |
FAC |
Heterozygous TC 1896T>C |
Grade 3-4 neutropenia |
18 in 30 |
Various regimen |
Homozygous CC 1896T>C |
Grade 3 neutropenia |
1 in 3 |
5-FU+Leucovorin |
* 1. Statistically significant difference in actual change of ANC and actual change
of percentage of neutrophil after the first or second cycle of chemotherapy.
2. Amino acid was changed from isoleucine to valine but the group of amino acid was the same (aliphatic amino acid).
** Group of amino acid was changed |